|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sun H, Wei Y, Tu H, et al: Expressions of
COX-2, PKC-alpha and miR-101 in gastric cancer and their
correlations. Nan Fang Yi Ke Da Xue Xue Bao. 33:559–562. 2013.(In
Chinese).
|
|
3
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Augello C, Vaira V, Caruso L, et al:
MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster
as a novel prognostic biomarker in hepatocellular carcinoma. Liver
Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ying Q, Liang L, Guo W, et al:
Hypoxia-inducible microRNA-210 augments the metastatic potential of
tumor cells by targeting vacuole membrane protein 1 in
hepatocellular carcinoma. Hepatology. 54:2064–2075. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fornari F, Gramantieri L, Giovannini C, et
al: MiR-122/cyclin G1 interaction modulates p53 activity and
affects doxorubicin sensitivity of human hepatocarcinoma cells.
Cancer Res. 69:5761–5767. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qu KZ, Zhang K, Li H, Afdhal NH and
Albitar M: Circulating microRNAs as biomarkers for hepatocellular
carcinoma. J Clin Gastroenterol. 45:355–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomimaru Y, Eguchi H, Nagano H, et al:
Circulating microRNA-21 as a novel biomarker for hepatocellular
carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Q, Fu H, Sun F, et al: miR-16 family
induces cell cycle arrest by regulating multiple cell cycle genes.
Nucleic Acids Res. 36:5391–5404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu HJ, Zhu J, Yang M, et al: A novel
method to monitor the expression of microRNAs. Mol Biotechnol.
32:197–204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bagga S, Bracht J, Hunter S, et al:
Regulation by let-7 and lin-4 miRNAs results in target mRNA
degradation. Cell. 122:553–563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lim LP, Lau NC, Garrett-Engele P, et al:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mathonnet G, Fabian MR, Svitkin YV, et al:
MicroRNA inhibition of translation initiation in vitro by targeting
the cap-binding complex eIF4F. Science. 317:1764–1767. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lau E, Kluger H, Varsano T, et al:
PKCepsilon promotes oncogenic functions of ATF2 in the nucleus
while blocking its apoptotic function at mitochondria. Cell.
148:543–555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang XC, Tian LL, Jiang XY, et al: The
expression and function of miRNA-451 in non-small cell lung cancer.
Cancer Lett. 311:203–209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Yang Y, Yang T, et al:
microRNA-22, downregulated in hepatocellular carcinoma and
correlated with prognosis, suppresses cell proliferation and
tumourigenicity. Br J Cancer. 103:1215–1220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ji J, Zhao L, Budhu A, et al: Let-7g
targets collagen type I alpha2 and inhibits cell migration in
hepatocellular carcinoma. J Hepatol. 52:690–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiong Y, Fang JH, Yun JP, et al: Effects
of microRNA-29 on apoptosis, tumorigenicity, and prognosis of
hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
|
|
20
|
Yang JS, Maurin T, Robine N, et al:
Conserved vertebrate mir-451 provides a platform for
Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl
Acad Sci USA. 107:15163–15168. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Godlewski J, Nowicki MO, Bronisz A, et al:
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to
metabolic stress in glioma cells. Mol Cell. 37:620–632. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Godlewski J, Bronisz A, Nowicki MO,
Chiocca EA and Lawler S: microRNA-451: A conditional switch
controlling glioma cell proliferation and migration. Cell Cycle.
9:2742–2748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bergamaschi A and Katzenellenbogen BS:
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes
breast cancer cell survival and endocrine resistance. Oncogene.
31:39–47. 2012.PubMed/NCBI
|
|
25
|
Gal H, Pandi G, Kanner AA, et al: miR-451
and imatinib mesylate inhibit tumor growth of glioblastoma stem
cells. Biochem Biophys Res Commun. 376:86–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hai T and Hartman MG: The molecular
biology and nomenclature of the activating transcription
factor/cAMP responsive element binding family of transcription
factors: activating transcription factor proteins and homeostasis.
Gene. 273:1–11. 2001. View Article : Google Scholar
|
|
27
|
Breitwieser W, Lyons S, Flenniken AM, et
al: Feedback regulation of p38 activity via ATF2 is essential for
survival of embryonic liver cells. Genes Dev. 21:2069–2082. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eferl R and Wagner EF: AP-1: a
double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhoumik A, Gangi L and Ronai Z: Inhibition
of melanoma growth and metastasis by ATF2-derived peptides. Cancer
Res. 64:8222–8230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhoumik A, Huang TG, Ivanov V, et al: An
ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits
their growth and metastasis. J Clin Invest. 110:643–650. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bhoumik A, Fichtman B, Derossi C, et al:
Suppressor role of activating transcription factor 2 (ATF2) in skin
cancer. Proc Natl Acad Sci USA. 105:1674–1679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vale-Cruz DS, Ma Q, Syme J and LuValle PA:
Activating transcription factor-2 affects skeletal growth by
modulating pRb gene expression. Mech Dev. 125:843–856. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura T, Okuyama S, Okamoto S, Nakajima
T, Sekiya S and Oda K: Down-regulation of the cyclin A promoter in
differentiating human embryonal carcinoma cells is mediated by
depletion of ATF-1 and ATF-2 in the complex at the ATF/CRE site.
Exp Cell Res. 216:422–430. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berger AJ, Kluger HM, Li N, et al:
Subcellular localization of activating transcription factor 2 in
melanoma specimens predicts patient survival. Cancer Res.
63:8103–8107. 2003.PubMed/NCBI
|
|
35
|
Choi JH, Cho HK, Choi YH and Cheong J:
Activating transcription factor 2 increases transactivation and
protein stability of hypoxia-inducible factor 1alpha in
hepatocytes. Biochem J. 424:285–296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song H, Ki SH, Kim SG and Moon A:
Activating transcription factor 2 mediates matrix
metalloproteinase-2 transcriptional activation induced by p38 in
breast epithelial cells. Cancer Res. 66:10487–10496. 2006.
View Article : Google Scholar
|
